Paras Biopharmaceuticals Finland

Key Areas of Work and Expertise

- Paras Biopharmaceuticals recombinant Biologics CDMO activities are centered and focused on development of:

  - Domain Antibodies (nanobodies, scFvs, diabodies, etc.)
  - Interleukins and IL variant proteins
  - Complex recombinant proteins
  - Recombinant Immunotoxins (RIT)
  - Recombinant vaccines/Virus Like Particles (VLP)
  - Plasmid DNAs

Paras Biopharma Strategy

Flawless Biologics™ Concept

- Like a Diamond with its unique and specific internal qualities, every Biologics is unique with its primary amino acid sequence, refolding and 3-D structure. Like a Flawless Diamond, biologics need to be developed and produced with extreme care and are difficult to produce.
- Paras Biopharmaceuticals, set up by a group of scientists and technologists with extensive experience, skills and successful track record in developing biologics, has expertise in producing next generation recombinant biologics that require highest level of knowledge & expertise. Paras Biopharmaceuticals main focus is to develop high quality biologics in the following categories-

    - Domain Antibodies (Nanobodies, Diabodies, scFvs)
    - Interleukins (IL) and IL fusion proteins
    - Recombinant Vaccines/Virus Like Particles (VLPs)
    - Plasmid DNA
    - Complex recombinant Proteins

- Paras Proprietary Technologies enable efficient production of recombinant biologics

Paras Biopharmaceuticals Finland Oy

Flawless Biologics™

a Paras Biopharma initiative

Paras Biopharmaceuticals Introduces The Concept Of Flawless Biologics™

Stay Tuned For Further Updates...

BD@parasbiopharma.com | T: +358 (0) 442709462 | www.parasbiopharma.com

Paras Biopharmaceuticals Finland Oy

Flawless Biologics™

A Paras Biopharma initiative

Enabling Flawless Biologics™

Building Quality Robustness in Development, Scale-up, and Production of Biopharmaceuticals

Enabling Biologics | Scale-up | Biologics CDMO and Biosimilars

BD@parasbiopharma.com | T: +358 (0) 442709462 | www.parasbiopharma.com

Paras Biopharmaceuticals Finland Oy

Flawless Biologics™

a Paras Biopharma initiative

Development and Process Optimization

Fully optimized
Low deviations
Accountability in development
Well-characterized process
Limited variability
Extensive profiling
State-of-art analytical methods
Scalable process

Paras Biopharma introduces its Flawless Biologics™ concept for **Development and Process Optimization** of recombinant proteins.

BD@parasbiopharma.com | T: +358 (0) 442709462 | www.parasbiopharma.com

Paras Biopharmaceuticals Finland Oy

Flawless Biologics™

a Paras Biopharma initiative

Scaled-up Production

Finnish Quality Excellence
Low regulatory risks
Addressing multiple batch production flexibility
World-class production suite
Logistical support and planning
Economical Production
Speed to market
Superior Quality

Paras Biopharma introduces its Flawless Biologics™ concept for **Scaled-up Production** of recombinant proteins.

BD@parasbiopharma.com | T: +358 (0) 442709462 | www.parasbiopharma.com

Paras Biopharma USP

Enabling and Enhancing Microbial Technologies

Paras Proprietary Technologies

Paras Proprietary Technologies enable efficient production of recombinant biologics

#	Paras Proprietary Technology	Value additions
1	Diabrid ® Technology	Optimized protocols and procedures are used along with economical method to facilitate highly efficient refolding of proteins.
2	Noblecleav® Technology	Incorporates gene construct with Paras Proprietary Partner and Spacers, enabling high expression yields for difficult and challenging proteins
3	Biomultifold® Technology	Enables achievement of multigram of proteins per liter of fermentation – yield enhancing technology
4	Cytofold StructQuant® Technology	Expression of recombinant proteins / peptides in the cytoplasm of proprietary E. Coli as fully active proteins

Proven Toolbox

(for recombinant biologics production)

Paras Biopharmaceuticals Finland Oy

Cytofold StructQuant® Protein Folding Technology

A first of kind tried and tested technology for production of soluble complex recombinant proteins in the cytoplasm of an *E. coli*.

Write to us at BD@parasbiopharma.com to know more about this technology and explore options to save time and costs by using this technology for your recombinant biologics candidates.

- Diabrid® Technology
- NobleCleav® Technology
- Biomultifold® Technology
- Cytofold StructQuant® Technology

Contact us to know more about Paras Biopharmaceuticals Proprietary Biologics Production Technologies

www.parasbiopharma.com

Are you looking to achieve a robust and consistent production process for your recombinant biologics?

Paras Biopharmaceuticals Finland Oy

Recombinant Biologics CDMO

E. coli / S. cerevisiae / Pichia

Talk to Paras Biopharma experts to know more about our tool box and proprietary technologies for economical production of your biologics.

- Diabrid® Technology
- NobleCleav® Technology
- Biomultifold® Technology
- Cytofold StructQuant® Technology

Contact us to know more about Paras Biopharmaceuticals Proprietary Biologics Production Technologies

BD@parasbiopharma.com | T: +358 (0) 442709462 | www.parasbiopharma.com

Paras Biopharma USP

Endotoxins Solutions

Paras Biopharmaceuticals Offers Knowledge-Driven Solution for Endotoxin Control

- Endotoxins form a major contaminants in commercially available proteins or biologically active substances. Endotoxins can initiate a strong immune response such as endotoxin shock, organ failure, tissue injury, disseminated intravascular coagulation, and even death.
- Due to the harmful effects of endotoxin, the FDA has limited the concentration of endotoxin
- Endotoxin removal is one of the most difficult tasks in downstream processes during protein purification. With years of experience in the field of recombinant protein development and Production, Paras Biopharmaceuticals deeply understands that removal of endotoxins from your biologicals is extremely important.
- We will be your reliable partner in effectively reducing the endotoxin levels and meeting strict regulatory requirements.
- We use a combination of unique technology knowledge and scientific understanding for effective removal of Endotoxins.

Paras Biopharmaceuticals Finland Oy

Your preferred CDMO for low Endotoxin recombinant Proteins

Endotoxins-Solution

Speak with our technical experts today to know about our custom approach on endotoxin removal

- Diabrid® Technology
- NobleCleav® Technology
- Biomultifold® Technology
- Cytofold StructQuant® Technology

BD@parasbiopharma.com | T: +358 (0) 442709462 | www.parasbiopharma.com

Paras Biopharmaceuticals Finland Oy

Endotoxins-Solution

Your preferred CDMO for low Endotoxin recombinant Proteins

Speak with our technical experts today to know about our custom approach on endotoxin removal

Enabling Process Development and Scaleup

Ensuring large scale batch production and supply

Diabrid® Technology | NobleCleav® Technology | Biomultifold® Technology | Cytofold StructQuant® Technology

BD@parasbiopharma.com | T: +358 (0) 442709462 | www.parasbiopharma.com

Paras Biopharmaceuticals Finland Oy

Your preferred CDMO for low Endotoxin recombinant Proteins

Endotoxins-Solution

For Bulk Recombinant Biologics

Endotoxins, part of cell walls of gram-negative bacteria, are a major contamination issue in production of recombinant biologics.

If left unchecked, they tend to cause major reactions and adverse effects.



Lipid A Bacterial Endotoxin

Paras Biopharmaceuticals is your recombinant biologics partner for helping you enable low endotoxin levels in bulk recombinant biologics material.

Enabling Process Development and Scaleup

Ensuring large scale batch production and supply

Speak with our technical experts today to know about our custom approach on endotoxin removal

Diabrid® Technology | NobleCleav® Technology | Biomultifold® Technology | Cytofold StructQuant® Technology

BD@parasbiopharma.com | T: +358 (0) 442709462 | www.parasbiopharma.com

Paras Biopharma USP

Flexible Timelines and Rapid Turnaround Times

Achieving Critical Milestones in Aggressive Timelines

- Paras Biopharmaceuticals team has developed expertise to work on aggressive timelines to achieve critical milestones for client projects. If you are looking for technical solutions in limited timeframe, we can be best suited for such Biologics Projects.
- Small, medium, and large companies look for aggressive timelines to scale up their processes and carry out IND-enabling Tox studies.
- It is crucial for the companies to achieve the milestones set before the next fundraising round.
- Considering the cash position for 1 to 3 years (especially small and mid sized companies), it becomes even more crucial to get the milestones achieved.
- Paras Biopharmaceuticals has flexible timeline schedules for accommodating projects with pressing deadlines.
- We can aim for a scalable production process in just 3 months from the time we have the gene sequence.

Paras Biopharmaceuticals Finland Oy

Your Single-Domain Antibodies CDMO

Gene Sequence to Scalable Process + Protein In Three Months*

Time Saved = Revenue Plus

- ✓ IL-fusion proteins
- ✓ Long Peptides
- ✓ Nanobodies
- ✓ Diabodies
- ✓ Peptibodies
- ✓ Domain antibodies
- ✓ scFvs

Paras Biopharma's **Feasibility Study Program** is a time-efficient project to express your difficult proteins in 3 months*

Diabrid® Technology | NobleCleav® Technology | Biomultifold® Technology | Cytofold StructQuant® Technology

Click here to know more about Paras Biopharmaceuticals Proprietary Biologics Production Technologies

BD@parasbiopharma.com | T: +358 (0) 442709462 | www.parasbiopharma.com

Paras Biopharmaceuticals Finland Oy, Kiviharjunlenkki 10, OULU, FI-90220 Finland

* Conditions apply

Paras Biopharmaceuticals Finland Oy

Your Single-Domain Antibodies CDMO

For scaled-up Microbial Production (750L scale) in **2 months**

Your Trusted Partner for Single-Domain Antibodies Development and Production

Offering Efficient Production of Recombinant Proteins in Microbial Systems

Diabodies; Peptibodies; IL-Fusion Proteins; scFvs; and many more...

Diabrid® Technology | NobleCleav® Technology | Biomultifold® Technology | Cytofold StructQuant® Technology

PARAS PROPRIETARY MICROBIAL TECHNOLOGIES

BD@parasbiopharma.com | T: +358 (0) 442709462 | www.parasbiopharma.com

Paras Biopharmaceuticals Finland Oy, Kiviharjunlenkki 10, OULU, FI-90220 Finland

Paras Biopharma USP

Unmatched Prices

Unique Solutions for Cash and Long-term Partnership

- Cost control (especially for smaller biotech companies) is very essential in the initial stages because of the restricted resources.
- A smart cost-control program will be beneficially in the long-term survival of the biotech company.
- Paras Biopharma offers attractive business models (risk reward based; manufacturing partnership) for companies to control cost at the initial stages.
- As a result, the companies will be able to support more programs in their pipeline thereby increasing the chances of success.

Paras Biopharma Expertise

A wide range of recombinant biologics

Paras Biopharmaceutical Unique Expertise

- Paras Biopharma expertise lies in bringing unique combination on quality focused product development, work on aggressive timelines & in limited cash. Productivity and Product Quality are our main attributes.
- Paras Biopharma focus is on development and production of next generation recombinant biologics that are produced in microbial systems (*E. coli*, *Pichia*, *Saccharomyces*).
- These next-generation biologics include:
  - Domain Antibodies (nanobodies, scFvs, diabodies, etc.)
  - Interleukins and IL variant proteins
  - Complex recombinant proteins
  - Recombinant Immunotoxins (RIT)
  - Recombinant vaccines/Virus Like Particles (VLP)
  - Plasmid DNAs
- Unlike simple recombinant proteins, these recombinant biologics require specialized technologies (Paras Biopharma possesses) and robust experience in working with these products.

Paras Biopharma Expertise

Interleukins (IL) and IL Variant Proteins & Domain Antibodies

Developing an Interleukin or IL variant protein candidates for unmet medical needs?

Paras Biopharmaceuticals Finland Oy

Interleukins Expert Recombinant Biologics CDMO

Talk today with Paras Biopharma to know how you could benefit through our experience of successfully developing such complex proteins in microbial systems.

- Diabrid® Technology
- NobleCleav® Technology
- Biomultifold® Technology
- Cytofold StructQuant® Technology

Contact us to know more about Paras Biopharmaceuticals Proprietary Biologics Production Technologies

BD@parasbiopharma.com | T: +358 (0) 442709462 | www.parasbiopharma.com

Paras Biopharmaceuticals Finland Oy

Your Single-Domain Antibodies CDMO

Paras Biopharmaceuticals - Domain Antibodies Production Technologies



scFv (single-chain fragment variable)

An scFv is a fusion protein and is made up of a variable heavy (VH) and a variable light (VL) chain domain linked by a linker peptide.

scFvs are mostly produced in microbial systems such as *E. coli*.

They offer many benefits over full length antibodies such as improved PK properties and improved reachability.

As a result, they have wide applications in therapeutics, diagnostics, and other research purposes.

Connect with Paras Biopharma to know more about our **Domain Antibody Production Technologies** and how we help our clients in their biologics development efforts

- Diabrid® Technology
- NobleCleav® Technology
- Biomultifold® Technology
- Cytofold StructQuant® Technology

BD@parasbiopharma.com | T: +358 (0) 442709462 | www.parasbiopharma.com

Paras Biopharmaceuticals Finland Oy, Kiviharjunlenkki 10, OULU, FI-90220 **Finland**

Paras Biopharma Expertise

Recombinant Vaccines/Virus-Like Particles (VLP) & Recombinant Immunotoxins (RIT)

Paras Biopharmaceuticals Finland Oy

Virus-Like Particle(VLP)

Your preferred CDMO for VLP development and Production

Paras Biopharmaceuticals is your preferred Recombinant Proteins Partner for developing VLPs and other recombinant-based vaccines. Get in touch with us today.



VLPs do not contain viral genetic materials (they are safe) and are increasingly explored for developing effective vaccines

More than 50% of VLPs are being developed as recombinant products in microbial platforms (Bacterial and Yeast), core competence of Paras Biopharmaceuticals

- Diabrid® Technology
- NobleCleav® Technology
- Biomultifold® Technology
- Cytofold StructQuant® Technology

BD@parasbiopharma.com | T: +358 (0) 442709462 | www.parasbiopharma.com

Recombinant ImmunoToxin (RIT)

Paras Biopharmaceuticals Finland Oy

Your preferred CDMO for antibody fragment-based RIT development

Are you developing RITs and other novel tumor-selective targeting ligands for unmet oncology and other therapeutic needs?

RIT is a recombinant protein linked to a toxin. The protein binds to a cell and is engulfed inside, and the toxins kill the target cells. The protein is usually an antibody fragment (scFv) that can be produced in microbial systems (*E. coli, Pichia, Saccharomyces*).

Enabling Process Development and Scaleup

Ensuring large scale batch production and supply

- Diabrid® Technology
- NobleCleav® Technology
- Biomultifold® Technology
- Cytofold StructQuant® Technology

Paras Biopharmaceuticals is your right partner for developing scFv and other antibody fragment-based RITs. Get in touch with us today.

BD@parasbiopharma.com | T: +358 (0) 442709462 | www.parasbiopharma.com

Paras Biopharmaceuticals Finland Oy

Recombinant ImmunoToxin (RIT)

Your preferred CDMO for antibody fragment-based RIT development

Immunotoxin Market Size is forecasted to grow at a CAGR of 7.8% from 2021 to 2026*

Finland-based recombinant biologics CDMO, Paras Biopharmaceuticals, is ready to contribute to this growing market. Contact us for **Efficient** and **Economical** development of your RIT.
Contact Mark.Jackson@parasbiopharma.com today.

* Source: Industry ARC Market Report

BD@parasbiopharma.com | T: +358 (0) 442709462 | www.parasbiopharma.com

Paras Biopharmaceuticals Finland Oy

Your preferred CDMO for antibody fragment-based RIT development

RITs and other novel tumor-selective targeting ligands in your pipeline?

Leverage on Paras Biopharma's experience to expedite development of your scFv and other antibody fragment-based RITs.

- ✓ Small scale development
- ✓ Process scale up
- ✓ Large scale optimized batches



Recombinant ImmunoToxin (RIT)

RIT is a recombinant protein linked to a toxin. The protein binds to a cell and is engulfed inside, and the toxins kill the target cells. The protein is usually an antibody fragment (scFv) that can be produced in microbial systems (*E. coli, Pichia, Saccharomyces*).

BD@parasbiopharma.com | T: +358 (0) 442709462 | www.parasbiopharma.com

Paras Biopharma Expertise

Plasmid DNA

Paras Biopharmaceuticals Finland Oy

Your Single-Domain Antibodies CDMO

Contract Manufacturing of Plasmid DNA
High Quality Grade and Scalable Process (gm to kg)



- ✓ High yielding Paras Biomultifold® Fermentation Technology
- ✓ Process and specifications tailored to suite your needs
- ✓ Plasmid DNA of various sizes
- ✓ Plasmid concentration from 1-20 mg/ml

pDNA applications:-

- ➢ Drug Substance for Cell and Gene Therapy
- ➢ DNA Vaccines
- ➢ Template for mRNA production

Diabrid® Technology | NobleCleav® Technology | Biomultifold® Technology | Cytofold StructQuant® Technology

BD@parasbiopharma.com | T: +358 (0) 442709462 | www.parasbiopharma.com

Paras Biopharmaceuticals Finland Oy, Kiviharjunlenkki 10, OULU, FI-90220 **Finland**

Paras Biopharmaceuticals Finland Oy

Your Single-Domain Antibodies CDMO

Customized Plasmid DNA Production by
PARAS PROPRIETARY MICROBIAL TECHNOLOGIES



- **Research and Preclinical-grade Plasmid DNA in short turnaround time and highly competitive price**
- **Material for IND enabling studies**

- ✓ High quality plasmid DNA (small & large scale production)
- ✓ Applications in Viral Vectors, DNA vaccines, CAR-T cell therapy and other needs
- ✓ Process and specifications tailored to suite your needs

Diabrid® Technology | NobleCleav® Technology | Biomultifold® Technology | Cytofold StructQuant® Technology

BD@parasbiopharma.com | T: +358 (0) 442709462 | www.parasbiopharma.com

Paras Biopharmaceuticals Finland Oy, Kiviharjunlenkki 10, OULU, FI-90220 **Finland**

Paras Biopharma Expertise

Complex Recombinant Proteins

Paras Biopharmaceuticals Finland Oy

Your Single-Domain Antibodies CDMO

Paras Biopharma

Continuing Leadership in Microbial Recombinant Protein Production

Microbial CDMO with strong customer focus

50+ batches on different molecules

Experience in working with:

- ***E. coli***
- ***S. cerevisiae***
- ***P. pastoris***
- ***B. subtilis*** and other microbial strains

Innovative, cost-saving services with maximum efficiency and Speed

Quality at different scales



DOE Approach

Diabrid® Technology

NobleCleav® Technology

Biomultifold® Technology

Cytofold StructQuant® Technology

BD@parasbiopharma.com | T: +358 (0) 442709462 | www.parasbiopharma.com

Paras Biopharmaceuticals Finland Oy, Kiviharjunlenkki 10, OULU, FI-90220 Finland

Paras Biopharmaceuticals Finland Oy

Your Single-Domain Antibodies CDMO

Unsure How To Solve The Complex Path Of A Gene Sequence To A GLP Tox Study Batch?

Offering Efficient Production of Recombinant Proteins in Microbial Systems



- ✓ **IL-fusion proteins**
- ✓ **Long Peptides**
- ✓ **Diabodies**
- ✓ **Peptibodies**
- ✓ **Domain antibodies**
- ✓ **scFvs**

Paras Biopharma **team** will utilize **Paras Proprietary Microbial Technologies** to help you lead your way from **Scratch to Batch**

Diabrid® Technology

NobleCleav® Technology

Biomultifold® Technology

Cytofold StructQuant® Technology

Click here to know more about Paras Biopharmaceuticals Proprietary Biologics Production Technologies

BD@parasbiopharma.com | T: +358 (0) 442709462 | www.parasbiopharma.com

Paras Biopharmaceuticals Finland Oy, Kiviharjunlenkki 10, OULU, FI-90220 Finland

Paras Biopharma

Recognition in the Industry

A big thanks to Nordic Selection Committee of NLS Invest 2021

for choosing Paras Biopharmaceuticals Finland Oy as one of the "***Rising Stars***" in the biopharma sector to join Nordic Life Science Invest.

Paras Biopharma continues to strive to develop innovative biologics for unmet medical needs as well as provide best biologics CDMO services.

Paras Biopharmaceuticals Finland Oy

Paras Biopharmaceuticals Finland Oy is recognised as one of the 30 Most Admired Companies to Watch 2021 by CIO Bulletin, USA

Paras Biopharmaceuticals has expertise to produce your Recombinant therapeutic Protein expression (in *E. coli S. cerevisiae and P. pastoris*).
The company's core competence is for your next generation biologics (domain antibodies, bispecific, Fab and scFv) using our proprietary microbial technologies.

30 Admired Companies to watch
CIO Bulletin 2021

Paras Biopharmaceuticals Finland Oy

30 Admired Companies to watch CIO Bulletin 2021

is named as

One of the Top 30 Admired Companies to Watch 2021

Your preferred Biologics CDMO / Recombinant Production Partner

Diabrid® Technology | NobleCleav® Technology | Biomultifold® Technology | Cytofold StructQuant® Technology

BD@parasbiopharma.com | T: +358 (0) 442709462 | www.parasbiopharma.com

Paras Biopharmaceuticals Finland Oy is named as one of the

Top Pharma Outsourcing Companies in Europe 2021

Your preferred Biologics CDMO / Recombinant Production Partner

Paras Biopharmaceuticals TOP PHARMA OUTSOURCING COMPANIES IN EUROPE 2021

Diabrid® Technology | NobleCleav® Technology | Biomultifold® Technology | Cytofold StructQuant® Technology

BD@parasbiopharma.com | T: +358 (0) 442709462 | www.parasbiopharma.com

ADDRESS
Paras Biopharmaceuticals Finland Oy,
Kiviharjunlenkki 10, Oulu, 90220, Finland
Phone: +358 442 709 462

EMAIL
bd@parasbiopharma.com
info@parasbiopharma.com

SOCIAL
www.parasbiopharma.com
twitter.com/parasbiopharma

Confidentiality & Disclaimer

By accepting these materials, the recipient agrees to be bound by the following obligations and limitations.

This presentation, including information contained in this disclaimer, is given to you in strict confidence. By receiving the presentation, you agree that no part of this presentation or disclaimer may be disclosed, distributed or reproduced to any third party without the consent of Paras Biopharmaceuticals Finland Oy ("PARAS").

This presentation is being provided for the sole purpose of providing the recipients with background information about PARAS business and bio-business in general. This presentation, including the information contained in this disclaimer, does not constitute an offer, invitation or recommendation to subscribe for or purchase any security and neither the presentation, disclaimer nor anything contained in them forms the basis of any contract or commitment.

Purpose. These materials have been prepared by for the exclusive use of the party to whom PARAS delivers these materials (together with its subsidiaries and affiliates, hereinafter the "Recipient").

No independent verification. The information in these materials have been obtained from the Recipient and/or other publicly available sources and has not been independently verified by PARAS and/or its subsidiaries, branches or affiliates (together, the " PARAS ") or any of their respective directors, officers, employees, agents, representatives or advisors (the "Representatives") or any other person.

No representation or warranty. No representation, warranty, or undertaking, either express or implied, is or will be given by PARAS or its Representatives as to or in relation to the accuracy, completeness, reliability or sufficiency of the information contained in these materials or as to the reasonableness of any assumption contained in these materials.

No liability. By accepting receipt of these materials, the Recipient acknowledges and agrees that to the maximum extent permitted by law and except in the case of fraud, each of PARAS and its Representatives expressly disclaims any and all liability that may arise from these materials.

No duty to update. These materials speak as at the date hereof (unless an earlier date is otherwise indicated in these materials) and in furnishing these materials, no obligation is undertaken nor is any representation or undertaking given by PARAS or its Representatives to provide the Recipient with additional information or to update, revise or reaffirm the information in these materials or to correct any inaccuracies therein which may become apparent.

Information only. These materials have been prepared solely for informational or educational purposes and do not suggest taking or refraining from any action. They do not constitute or contain an invitation, solicitation or an offer to buy or sell any securities or related financial instruments or any of the assets, business, or undertakings described herein, and they do not constitute, and should not be construed as, a proposal, a commitment or an offer to arrange, underwrite, syndicate or otherwise provide any debt financing.

No distribution. These materials have been prepared on a confidential basis solely for your use and benefit; provided that you and any of your employees, representatives, or other agents may disclose to any and all persons, without limitation of any kind, the tax treatment and tax structure of the transaction and all materials of any kind (including opinions or other tax analyses) that are provided to you relating to such tax treatment and tax structure. Distribution of these materials to any person other than you and those persons retained to advise you, who agree to maintain the confidentiality of these materials and be bound by the limitations outlined herein, is unauthorized.

PARAS specifically prohibits the redistribution or reproduction of these materials in whole or in part without the prior written permission of PARAS and PARAS accepts no liability whatsoever for the actions of third parties in this respect.